Reviewer’s report

Title: Analysis of B7-H4 expression in metastatic pleural adenocarcinoma and therapeutic potential of its antagonists

Version: 0 Date: 06 May 2017

Reviewer: Zong Sheng Guo

Reviewer’s report:

The authors have explored the expression of an important regulatory molecule, B7-H4, in malignant pleural effusion (MPE), and started to elucidate its functions in this particular type of malignancy. This is a potentially important study.

There are a few (major and minor) issues in this study:

1. Major issue is the data presentations. (1). Figure 4C. No P value is presented. (2). Figure 5. A better way to present the data is to show data (CT scan) in both groups of mice, before and after treatment with either isotype control mAB or anti-B7-H4 mAb.

2. Better Introduction and Discussion, with a few more references:

A. Some more introduction on the background information on what has been done and shown:


B. Most studies have shown an inhibitory role of B7-H4 in the antitumor immunity, while a few studies have pointed to the opposite. In this regard, it is good to discuss this issue and cited a few relevant papers.


Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.
Yes

**Does the work include the necessary controls?**
If not, please specify which controls are required in your comments to the authors.

Yes

**Are the conclusions drawn adequately supported by the data shown?**
If not, please explain in your comments to the authors.

Yes

**Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?**
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

**Quality of written English**
Please indicate the quality of language in the manuscript:

Needs some language corrections before being published

**Declaration of competing interests**
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.
I declare that I have no competing interests.

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal